These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9368336)

  • 1. Purging of peripheral blood progenitor cell autografts and treatment of minimal residual disease.
    Brugger W; Scheding S; Bock T; Ziegler B; Kanz L
    Stem Cells; 1997; 15 Suppl 1():159-65. PubMed ID: 9368336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo manipulation of hematopoietic stem and progenitor cells.
    Kanz L; Brugger W; Scheding S
    Stem Cells; 1998; 16 Suppl 1():199-204. PubMed ID: 11012163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
    Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
    Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of immunomagnetic selection in purging autologous peripheral blood progenitor cell of breast cancer patients].
    Han X; Shi Y; Zhang W
    Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(3):203-6. PubMed ID: 11953162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical applications of CD34(+) peripheral blood progenitor cells (PBPC).
    Vogel W; Scheding S; Kanz L; Brugger W
    Stem Cells; 2000; 18(2):87-92. PubMed ID: 10742380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cellular therapy for intensification in oncology and hematology: manipulation of peripheral blood stem-cell products].
    Douay L
    Bull Cancer; 2001 Sep; 88(9):826-32. PubMed ID: 11604353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous and allogeneic transplantation with peripheral blood CD34+ cells: a pediatric experience.
    Watanabe T; Kawano Y; Watanabe A; Takaue Y
    Haematologica; 1999 Feb; 84(2):167-76. PubMed ID: 10091416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex vivo expansion of hematopoietic cells and their clinical use.
    Aglietta M; Bertolini F; Carlo-Stella C; De Vincentiis A; Lanata L; Lemoli RM; Olivieri A; Siena S; Zanon P; Tura S
    Haematologica; 1998 Sep; 83(9):824-48. PubMed ID: 9825579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of tumor cell depletion by combining immunomagnetic positive selection of CD34-positive hematopoietic stem cells and negative selection (purging) of tumor cells.
    Hoppe B; Mohr M; Roots-Weiss A; Kienast J; Berdel WE
    Bone Marrow Transplant; 1999 Apr; 23(8):809-17. PubMed ID: 10231144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stem cell purging ex vivo.
    Seiden MV; Anderson KC
    J Infus Chemother; 1996; 6(1):17-22. PubMed ID: 8748002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex-vivo purging of hematopoietic progenitor cells.
    de Lima M; Shpall EJ
    Curr Hematol Rep; 2004 Jul; 3(4):257-64. PubMed ID: 15217555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device--a local experience.
    Leong CF; Habsah A; Teh HS; Goh KY; Fadilah SA; Cheong SK
    Malays J Pathol; 2008 Jun; 30(1):31-6. PubMed ID: 19108409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ex vivo and in vivo purging for PBSCT].
    Moriyama Y
    Rinsho Byori; 1999 May; Suppl 110():79-84. PubMed ID: 10475035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo expansion of mafosfamide-purged PBPC products.
    McNiece I; Civin C; Harrington J; Kellner J; Malehorn M; Turney J; Barber J; Jones R
    Cytotherapy; 2006; 8(5):459-64. PubMed ID: 17050250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
    Choi D; Perrin M; Hoffmann S; Chang AE; Ratanatharathorn V; Uberti J; McDonagh KT; Mulé JJ
    Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells .
    Haas R; Murea S
    Cytokines Mol Ther; 1995 Dec; 1(4):249-70. PubMed ID: 9384679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo expansion of CD34-positive peripheral blood progenitor cells from patients with non-Hodgkin's lymphoma: no evidence of concomitant expansion of contaminating bcl2/JH-positive lymphoma cells.
    Yao M; Fouillard L; Lemoine FM; Bouchet S; Firat H; Andreu G; Gorin NC; Douay L; Lopez M
    Bone Marrow Transplant; 2000 Sep; 26(5):497-503. PubMed ID: 11019838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purging peripheral blood progenitor cell grafts from lymphoma cells: quantitative comparison of immunomagnetic CD34+ selection systems.
    Paulus U; Dreger P; Viehmann K; von Neuhoff N; Schmitz N
    Stem Cells; 1997; 15(4):297-304. PubMed ID: 9253114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [High dose therapy with transplantation of autologous peripheral hematopoietic stem cells. I. Basic principles and clinical development].
    Gunsilius E; Petzer A; Gastl G
    Acta Med Austriaca; 1997; 24(3):97-101. PubMed ID: 9312975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should we purge?
    Bensinger WI
    Bone Marrow Transplant; 1998 Jan; 21(2):113-5. PubMed ID: 9489625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.